Moderna (MRNA) Net Cash Flow Growth (5y) (2023 - 2026)
Powered by 
Analysis
Moderna (MRNA) Net Cash Flow Growth (5y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.69% |
| Mar 31, 2026 | -17.55% |
| Dec 31, 2025 | 5.53% |
| Sep 30, 2025 | 10.38% |
| Jun 30, 2025 | -17.63% |
| Mar 31, 2025 | -31.57% |
| Dec 31, 2024 | 35.07% |
| Sep 30, 2024 | -108.88% |
| Jun 30, 2024 | 25.91% |
| Mar 31, 2024 | -40.64% |
| Dec 31, 2023 | -15.45% |
| Sep 30, 2023 | -103.46% |
| Jun 30, 2023 | 48.22% |
| Mar 31, 2023 | 49.27% |